Immix Biopharma, Inc.
Immix Biopharma, Inc. (IMMX): 4 pipeline candidates · 3 upcoming catalysts · ~28 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
27.6 months
D/E 0.14 · 4% dilution
Lead: Phase 2
4 candidates
3 upcoming, next in ~104d
N/A
A transparent, data-derived signal for Immix Biopharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$603.0M
Cash
$79.3M
Quarterly Burn
$9.8M
Runway
27.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Upcoming Catalysts (3)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
73
Total value held
$242.5M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 9,604,004 | $87.4M |
| vanguard capital management llc | 3,575,988 | $32.6M |
| eventide asset management, llc | 2,549,019 | $23.2M |
| millennium management llc | 1,750,200 | $15.9M |
| marshall wace, llp | 1,641,552 | $15.0M |
| franklin resources inc | 969,066 | $8.8M |
| susquehanna international group, llp | 588,794 | $5.4M |
| blue owl capital holdings lp | 547,552 | $5.0M |
| blackrock, inc. | 468,377 | $4.3M |
| geode capital management, llc | 463,384 | $4.2M |
Showing top 10 of 73 institutional holders of Immix Biopharma, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Immix Biopharma, Inc.'s pipeline?
Immix Biopharma, Inc. (IMMX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Immix Biopharma, Inc.'s lead drug candidate?
Immix Biopharma, Inc.'s most advanced tracked candidate is imx-110 (Phase 2) for Solid tumors (initially soft tissue sarcoma).
What is Immix Biopharma, Inc.'s next catalyst?
Immix Biopharma, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: nxc-201" — expected September 30, 2026.
What is Immix Biopharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Immix Biopharma, Inc. has approximately 27.6 months of cash runway.
What is Immix Biopharma, Inc.'s market capitalization?
Immix Biopharma, Inc.'s market capitalization is approximately $603.0M.
Get the full picture on Immix Biopharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.